Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03681028 (Pilot Study Testing Feasibility of Individualized Therapy for Recurrent Glioblastoma), which is not on this map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pilot Study Testing Feasibility of Individualized Therapy for Recurrent Glioblastoma
TypeinterventionalSponsorJennifer ClarkeRan2018 to 2024Enrolled30ConditionsRecurrent GlioblastomaArmsIndividualized therapy
3 · Its place in the literature
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors.
Jiaying ChenDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-4297-1545
Nancy Ann Oberheim BushDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-8302-5008
Jennifer A GrabowskyDepartment of Pharmaceutical Services, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-4871-0741
Cassie KlineDepartment of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.ORCID 0000-0001-7765-7690
Deanna L KroetzDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-5997-270X
Jennie W TaylorDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-3980-5626
Javier Villanueva-MeyerDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-5910-0757
Annette M MolinaroDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-9854-7404
John F de GrootDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-1454-6461
Nicholas A ButowskiDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-5162-2406
Meghan TedescoDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.ORCID 0009-0008-3777-4700
Jane RabbittDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.ORCID 0009-0006-5754-4430
Joanna J PhillipsDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-3789-8120
Shawn Hervey-JumperDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-4699-260X
Manish K AghiDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-2949-2227
Mitchel S BergerDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-1983-4892
Edward F ChangDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-2480-4700
Susan M ChangDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.ORCID 0009-0001-2084-3959
David A SolomonDepartment of Pathology, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-4571-7999
Jennifer L ClarkeDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-8054-7342
Funding
Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4M
Training Program in Translational Brain Tumor ResearchT32CA151022 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2010 to 2026
$6.6M
Retroviral RLI immunomodulatory gene therapy for glioblastomaR01NS123808 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Manish Aghi · 2022 to 2026
$2.1M
Investigation of a novel molecular driver of schwannoma nerve sheath tumorsR01NS140465 · NINDS · STANFORD UNIVERSITY · PI David A. Solomon · 2025 to 2026
$1.1M
Ben and Catherine Ivy Foundation (BCIF) Emerging Leader AwardGilbert Family Foundation (GFF) Next Generation NF1 Models AwardMorgan Adams Foundation Solomon Lab brain tumor researchNCI NIH HHS P50 CA097257NCI NIH HHS T32 CA151022NINDS NIH HHS R01 NS123808NINDS NIH HHS R01 NS140465Sandler Foundation UCSF Glioblastoma Precision Medicine ProgramSandler Foundation UCSF Program for Breakthrough Biomedical Research
6 · The paper itself
Abstract
purposeExisting salvage therapies for recurrent glioblastoma (rGBM) have limited efficacy, with a median survival of approximately 9 months. Given the complex molecular heterogeneity of GBM, single-target approaches have consistently failed as a treatment strategy. We conducted a phase I clinical trial to assess the feasibility, safety, and efficacy of a genomically tailored multiagent regimen in 30 adults with surgically treated rGBM. PATIENTS AND
methodsAdults with IDH wild-type GBM (n = 29) or grade 4 IDH-mutant astrocytoma (n = 1) were consented and underwent clinically indicated surgery for recurrent disease. Comprehensive genomic profiling was performed on the recurrent tumors, and results for each patient were discussed at an individualized molecular tumor board to determine a personalized treatment regimen combining up to four FDA-approved drugs, including one cytotoxic agent as the backbone.
resultsA total of 12 drugs were used in 18 combinations-the most common regimen was lomustine, afatinib, and abemaciclib (n = 8). The most common toxicities included cytopenias, rash, and gastrointestinal symptoms, requiring frequent dose reductions. Measured from surgery at trial enrollment, progression-free survival at 6 months was 40%, overall survival (OS) at 9 months was 73%, and median OS was 12.7 months. After trial therapy, genomic profiling performed on subsequent recurrent tumor specimens identified genetic evolution corresponding to putative treatment resistance mechanisms.
conclusionsImplementation of individualized treatment regimens in a timely fashion was feasible for patients with surgically resectable rGBM. Overall efficacy was not significantly improved compared with a contemporary patient cohort treated without experimental regimens, with full dosing of most combination therapies limited by toxicities.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma. · full record | OpenQuestion